Dentsply Q3 Earnings Miss: Is XRAY a Sell?
💡 Key Takeaway
Dentsply's Q3 earnings miss and weak segment performance, especially in orthodontics and implants, raise concerns about the company's near-term growth prospects.
Dentsply Q3 Earnings: Misses Across the Board
Dentsply Sirona (XRAY) reported third-quarter earnings that fell short of Wall Street estimates on both the top and bottom lines. The dental equipment maker posted revenue of $947 million, missing the consensus estimate of $977 million and marking a 7.5% decline year-over-year.
Earnings per share came in at $0.44, below the expected $0.49. The company's adjusted operating income also took a hit, with the Connected Technology Solutions segment reporting a loss of $3 million versus an estimated profit of $12.29 million.
Segment performance was weak across the board. Connected Technology Solutions revenue dropped 11.2% year-over-year, while Orthodontic and Implant Solutions plunged 16.6%. The only bright spot was Wellspect Healthcare, which saw revenue rise 5.1%.
Management acknowledged the challenging environment, citing macroeconomic headwinds and softer demand in certain markets. The stock has been under pressure, and the weak results have led to a Zacks Rank #4 (Sell) rating, indicating expectations for underperformance in the near term.
What This Means for Me
Why This Earnings Miss Matters for Investors
The earnings miss is significant because it reflects broader challenges in the dental equipment industry, including supply chain disruptions, inflation, and slowing demand. Dentsply's heavy exposure to discretionary dental procedures makes it vulnerable to economic downturns.
The steep decline in Orthodontic and Implant Solutions is particularly concerning, as these are high-margin segments that drive profitability. The negative operating income in Connected Technology Solutions also signals operational inefficiencies that could persist.
Investors should note that the company's guidance may be revised downward, putting further pressure on the stock. With a Zacks Rank #4 (Sell), analyst sentiment is clearly negative, and the stock could face additional downside.
However, some may argue that the bad news is already priced in, and the stock could be a value play if the company can execute a turnaround. But given the lack of near-term catalysts, caution is warranted.
Stock to Watch
| Stocks | Impact | Analysis | |
|---|---|---|---|
| XRAY | Negative | Dentsply missed Q3 estimates and showed significant weakness in key segments, leading to a Zacks Sell rating and potential further downside. |
Source: Zacks Investment Research
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight

Avoid XRAY for now; wait for clearer signs of stabilization before considering a position.
The company's weak performance across major segments, combined with negative analyst sentiment and macroeconomic headwinds, suggests continued pressure on the stock. Until management demonstrates a credible turnaround plan and improvement in key metrics, the risk/reward is unfavorable.
What This Means for Me

Read More
Dentsply Sirona Stock: Guidance Cut, But Long-Term Bet Remains
Neutral Dentsply Sirona's guidance cut reflects near-term pain, but heavy investment in clinical education and commercial execution could drive long-term growth, making XRAY a speculative turnaround play.
XRAYNov 16, 2026Definium Therapeutics: 3 Key Takeaways for Long-Term Investors
Bullish Definium Therapeutics' positive Phase 3 data and $1.05 billion cash runway position it for a potential 2027 NDA filing, but regulatory and commercial risks remain.
DFTXNov 16, 2026Nvidia CEO Shakeup: What Huang's Exit Means for NVDA
Bearish Nvidia's leadership crisis creates near-term uncertainty, but the company's strategic position and potential financing discipline could benefit long-term investors.
NVDASPCXSHOPNov 16, 2026

